Tenet Healthcare
THC
$162.06
+0.43%
Tenet Healthcare Corporation is a major healthcare services organization operating acute and specialty hospitals, ambulatory surgery centers, and outpatient facilities across the United States, primarily in the South, and also provides revenue cycle management solutions through its Conifer segment. The company is a significant player in the hospital and medical care facilities industry, known for its extensive network of owned and operated facilities. The current investor narrative is focused on the company's ability to navigate a challenging operating environment, as recent earnings reports have highlighted a divergence between strong profitability and softer-than-expected revenue, driven by an unfavorable patient admissions mix, which is a key debate point regarding its near-term growth trajectory.…
THC
Tenet Healthcare
$162.06
THC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $210.68 and implied upside of +30.0% versus the current price.
Average Target
$210.68
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$130 - $211
Analyst target range
Analyst coverage for Tenet Healthcare is limited, with only 4 analysts providing estimates, which is low for a company of its market cap and can lead to higher volatility and less efficient price discovery. The consensus leans bullish, as evidenced by recent institutional ratings from firms like Guggenheim, Mizuho, and Barclays all maintaining 'Buy' or 'Outperform' equivalents throughout February and March 2026, indicating sustained positive sentiment among covering firms. The average revenue estimate for the forward period is $24.08 billion, with a tight range from a low of $23.74 billion to a high of $24.53 billion, suggesting analysts have relatively high conviction in the company's near-term revenue trajectory despite recent softness.
Bulls vs Bears: THC Investment Factors
The evidence presents a stark conflict between strong underlying fundamentals and severe technical/price momentum deterioration. The bull case is anchored in Tenet's robust profitability (33.34% ROE), massive cash generation ($2.53B FCF), and deeply discounted valuation (9.10x forward P/E). The bear case is driven by the stock's catastrophic -31.9% three-month decline, decelerating revenue growth (8.97% YoY in Q4), and high financial leverage (D/E of 3.12). Currently, the bear side has stronger evidence as the severe price action and revenue softness are immediate, tangible realities. The single most important tension is whether the company's strong cash flow and profitability can soon reverse the negative patient mix and sentiment, justifying the low valuation, or if operational headwinds will persist, validating the market's punitive re-rating.
Bullish
- Strong Profitability and Cash Flow: Tenet generated a robust 33.34% ROE and $2.53 billion in TTM free cash flow, demonstrating exceptional capital efficiency and financial flexibility. The Q4 2025 net margin of 6.70% and operating margin of 15.4% confirm the underlying business model's strength despite revenue headwinds.
- Attractive Valuation Multiples: The stock trades at a forward P/E of 9.10x and a P/S of 0.84x, which are low relative to its own historical range and typical for the capital-intensive healthcare sector. The 28.5% discount of the forward P/E to the trailing P/E of 12.73x implies the market expects significant earnings growth.
- Analyst Consensus Remains Bullish: Despite recent stock weakness, covering firms like Guggenheim, Mizuho, and Barclays maintained 'Buy' or 'Outperform' ratings in Q1 2026. This sustained positive sentiment suggests analysts view the current price dislocation as an opportunity, not a fundamental breakdown.
- Deeply Oversold Technical Condition: The stock is down 31.9% over three months and sits just 14.8% above its 52-week low of $146.6, indicating severe negative momentum exhaustion. This oversold condition, with a relative strength of -18.26 vs. the S&P 500 over one month, sets up for a potential technical rebound on any positive catalyst.
Bearish
- Severe Revenue Growth Deceleration: Q4 2025 revenue growth slowed to 8.97% YoY, a sequential deceleration from earlier quarters, with recent news blaming an unfavorable patient admissions mix. This core operational softness, if persistent, directly challenges the growth narrative supporting the valuation.
- Pronounced and Persistent Downtrend: The stock has underperformed the S&P 500 by 44.5 points over three months and is in a clear downtrend, having fallen 23.16% over six months. This negative price action reflects sustained selling pressure and a lack of buyer conviction, which can become a self-fulfilling prophecy.
- High Financial Leverage: A debt-to-equity ratio of 3.12 signifies significant financial risk, especially in a rising interest rate environment. While cash flow is strong, this leverage amplifies earnings volatility and constrains strategic flexibility if operational performance weakens further.
- Volatile and Compressing Margins: Gross margin collapsed from 82.26% in Q2 2025 to 41.52% in Q4 2025, indicating extreme quarterly volatility in cost structure. This inconsistency makes future profitability difficult to forecast and raises questions about operational stability.
THC Technical Analysis
The stock is in a pronounced downtrend, having declined 31.90% over the past three months and 23.16% over the past six months, significantly underperforming the broader market. As of the latest close at $161.37, the price sits just 14.8% above its 52-week low of $146.6, positioning it near the bottom of its annual range, which suggests the stock is deeply oversold and may present a value opportunity, though it also indicates persistent negative momentum. Recent momentum remains sharply negative, with the stock down 13.66% over the past month, a continuation of the longer-term downtrend, and its relative strength versus the S&P 500 is a stark -18.26 points over the same period, confirming severe weakness. Key technical support is clearly defined at the 52-week low of $146.6, while resistance lies at the 52-week high of $247.21; a breakdown below support could trigger further selling, while a recovery would need to overcome significant overhead supply. The stock's beta of 1.30 indicates it is 30% more volatile than the market, which amplifies both downside risk and potential upside during a recovery, a critical factor for risk management.
Beta
1.28
1.28x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$147-$247
Price range past year
Annual Return
-5.7%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | -16.7% | -0.0% |
| 3m | -31.6% | +8.7% |
| 6m | -22.8% | +8.0% |
| 1y | -5.7% | +23.1% |
| ytd | -18.7% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Revenue growth has been positive but is showing signs of deceleration; the most recent Q4 2025 revenue was $5.53 billion, representing a year-over-year growth of 8.97%, yet this follows a quarter (Q3 2025) where revenue was $5.29 billion, indicating a sequential slowdown from the strong growth seen earlier in the year. The company is profitable, with Q4 2025 net income of $371 million and a net margin of 6.70%, though gross margin for the quarter was 41.52%, which has compressed from the unusually high 82.26% reported in Q2 2025, reflecting significant quarterly volatility in cost structure. Profitability metrics are solid, with a Return on Equity (ROE) of 33.34% and a trailing twelve-month free cash flow of $2.53 billion, demonstrating strong cash generation. The balance sheet carries a high degree of financial leverage, with a debt-to-equity ratio of 3.12, but this is supported by a healthy current ratio of 1.76 and substantial operating cash flow, suggesting the company can service its obligations while funding operations internally.
Quarterly Revenue
$5.5B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 12.73x, while the forward PE is 9.10x, with the forward multiple being 28.5% lower, indicating the market expects significant earnings growth in the coming year. Compared to its own historical range, the current trailing PE of 12.73x is below the multi-year highs seen above 40x in 2021 but is also below the more recent average from 2023-2025, which often fluctuated between 7x and 17x, suggesting the stock is trading at a reasonable level relative to its own history, neither excessively cheap nor expensive. The stock trades at a Price-to-Sales (PS) ratio of 0.84x and an EV-to-Sales of 1.33x, which are low multiples typical for the capital-intensive healthcare facilities sector, indicating the market is assigning a modest valuation to its revenue base.
PE
12.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on Tenet's high debt load, with a debt-to-equity ratio of 3.12, which, while serviceable by strong cash flow ($2.53B FCF), creates vulnerability if interest rates rise or earnings decline. Revenue growth deceleration to 8.97% YoY in Q4 2025, attributed to an unfavorable patient mix, poses a core business risk if it indicates a structural shift rather than a temporary issue. Furthermore, gross margin volatility—plummeting from 82.26% to 41.52% between Q2 and Q4 2025—signals potential instability in cost management and reimbursement rates, making future earnings less predictable.
Market & Competitive Risks are heightened by the stock's valuation compression risk; while the forward P/E of 9.10x seems cheap, it could compress further if growth stalls. The stock's beta of 1.30 means it is 30% more volatile than the market, amplifying downside during sector-wide sell-offs or negative healthcare policy news. Competitive pressure from other hospital networks and outpatient centers could intensify, squeezing Tenet's pricing power and admissions volume, exacerbating the recent revenue mix challenges highlighted in April 2026 news.
Worst-Case Scenario involves a continuation of the unfavorable admissions mix leading to a sequential revenue miss and margin compression, triggering debt covenant concerns given the high leverage. This could result in analyst downgrades from the current bullish stance, leading to a loss of institutional support. The realistic downside would be a retest and break below the key 52-week low support of $146.6. From the current price of $161.37, this implies a potential loss of approximately -9.2%. A more severe bear case, factoring in a sector de-rating, could see the stock fall toward the $130-$140 range, representing a downside of -13% to -19% from current levels.